COVID-19 Vaccine
AGC Biologics Supports Omicron-Based Vaccine Candidate Manufacturing with Starting Material
AGC Biologics
PR-M02-22-07Feb 09, 2022
COVID-19 Vaccine
Pfizer and BioNTech to Vaccinate Olympic Athletes in Tokyo
Pfizer
PR-M05-21-014May 20, 2021
Emergency Use
Pfizer and BioNtech Receive First U.S. Authorization for Emergency Use of Covid-19 Vaccine in Adolescents
Pfizer
PR-M05-21-007May 11, 2021
COVID-19
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
Pfizer
PR-M11-20-007Nov 10, 2020
M&A
BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021
Nice Insight
PR-M09-20-28Sep 24, 2020
COVID-19 Vaccine
Pfizer and BioNTech Announce Data from Preclinical Studies of COVID-19 Vaccine Candidate
Pfizer
PR-M09-20-NI-15Sep 11, 2020
Collaboration
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo Combination in Melanoma
BioNTech
PR-M08-20-NI-06Jul 31, 2020
COVID-19 Vaccine
Pfizer and BioNTech to Receive $2 Billion from U.S. Government
Pfizer
PR-M07-20-NI-33-1383Jul 23, 2020
COVID-19 Vaccine
Pfizer and BioNTech Report T Cell Response in COVID-19 Vaccine
Pfizer
PR-M07-20-NI-30Jul 21, 2020
COVID-19 Vaccine
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Pfizer
PR-M06-20-NI-042Jul 02, 2020
Vaccine
Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine
BioNTech
PR-M03-20-NI-031Mar 20, 2020
Collaboration
BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs
BioNTech
PR-M09-19-NI-033Sep 12, 2019
Series B Financing
BioNTech Raises USD 325 Million in an Upsized Series B Financing to Further Advance Individualized Immuno-Oncology Pipeline
BioNTech
PR-M07-19-NI-025Jul 10, 2019
Vaccine
Thermo Fisher Scientific to Support mRNA-based Vaccine Candidate Production for BioNTech
Thermo Fisher Scientific
PA2984Feb 28, 2019
Collaboration
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
BioNTech
PR-M09-18-NI-052Sep 18, 2018